Get the Stockscreener App
112.33
10.27%
10.46
After Hours:
112.17
-0.16
-0.14%
Guardant Health Inc stock is traded at $112.33, with a volume of 4.40M.
It is up +10.27% in the last 24 hours and up +10.11% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$101.87
Open:
$101.92
24h Volume:
4.40M
Relative Volume:
1.79
Market Cap:
$14.59B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-26.49
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
+11.66%
1M Performance:
+10.11%
6M Performance:
+122.44%
1Y Performance:
+213.07%
1-Day Range:
$101.92
$112.44
1-Week Range:
$97.31
$112.44
52-Week Range:
$34.55
$112.44
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
112.33 | 13.23B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
620.72 | 229.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.59 | 166.25B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
706.83 | 54.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.60 | 40.52B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
240.53 | 39.95B | 15.90B | 1.28B | 2.21B | 7.2842 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health stock jumps 7% as Evercore downgrades — what investors watch next - ts2.tech
GH Virtual Meeting Scheduled by BTIG for January 12 - GuruFocus
Guardant Health (NASDAQ:GH) Stock Rating Lowered by Evercore ISI - MarketBeat
GH: Evercore ISI Group Downgrades Guardant Health While Raising Price Target | GH Stock News - GuruFocus
GH: Guggenheim Raises Price Target for Guardant Health to $115 | - GuruFocus
VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Guardant Health, Inc. $GH - MarketBeat
Allspring Global Investments Holdings LLC Makes New $39.52 Million Investment in Guardant Health, Inc. $GH - MarketBeat
What analysts say about Guardant Health Inc stockBear Market Strategies & Explosive Growth Opportunities - earlytimes.in
Calamos Advisors LLC Takes $2.78 Million Position in Guardant Health, Inc. $GH - MarketBeat
Canaccord Names Guardant Health (GH) Top Life Science Pick, Cites Strong Growth and Low Downside - Finviz
Behavioral Patterns of GH and Institutional Flows - Stock Traders Daily
Osaic Holdings Inc. Grows Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (GH) Jumps to New Record High on Earnings Blowout, Bullish Outlook - MSN
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Joplin Globe
Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening - The Joplin Globe
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - The Motley Fool
Multiple analysts lift Guardant Health, Inc. (GH) targets on screening and data growth - MSN
Capricorn Fund Managers Ltd Takes $2.26 Million Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Genomics in Cancer Care Market to Reach USD 72.87 Billion by 2033 | - openPR.com
Multiple Analysts Lift Guardant Health, Inc. (GH) Targets on Screening and Data Growth - Yahoo Finance
Guardant Health (GH) Leads Healthcare Stocks with 226.48% YTD Ga - GuruFocus
Guardant Health is the top performing healthcare services stock YTD (GH:NASDAQ) - Seeking Alpha
7 Most Promising Gene Editing Stocks According to Analysts - Insider Monkey
Guardant Health (GH) Receives Buy Rating and $125 Price Target f - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Guardant Health (NASDAQ:GH) Stock Price - MarketBeat
(GH) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Why Guardant Health Inc. (5GH) stock could be top winnerWeekly Investment Recap & Weekly Momentum Picks - ulpravda.ru
How Guardant Health Inc. (5GH) stock reacts to stronger dollarGap Up & Weekly Sector Rotation Insights - DonanımHaber
First Week of February 2026 Options Trading For Guardant Health (GH) - Nasdaq
How strong is Guardant Health Inc. stock balance sheetJuly 2025 Highlights & Weekly Breakout Stock Alerts - DonanımHaber
Can Guardant Health Inc. (5GH) stock hold up in economic slowdown2025 Big Picture & Low Drawdown Trading Techniques - DonanımHaber
Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health (GH) CIO reports RSU vesting and tax-share withholding - Stock Titan
Guardant Health Insider Move Sparks Fresh Buzz on Wall Street - TipRanks
[Form 4] Guardant Health, Inc. Insider Trading Activity - Stock Titan
Guardant Health (GH) CMO Craig Eagle reports RSU vesting and tax share sale - Stock Titan
Guardant Health (NASDAQ:GH) Director Sells $11,769.36 in Stock - MarketBeat
Dir Tariq Sells 116 ($11.8K) Of Guardant Health Inc [GH] - TradingView — Track All Markets
Guardant Health (GH) director exercises RSUs into 232 common shares - Stock Titan
Guardant Health (GH) director reports 116-share stock sale and holdings - Stock Titan
Will Guardant Health Inc. stock deliver better than expected guidance2025 Key Lessons & Proven Capital Preservation Tips - Улправда
Guardant Health Insider Sold Shares Worth $9,402,220, According to a Recent SEC Filing - marketscreener.com
Insider Sell: Helmy Eltoukhy Sells 90,565 Shares of Guardant Hea - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Natera (NTRA) - The Globe and Mail
Insider Selling: Guardant Health (NASDAQ:GH) CEO Sells $9,402,458.30 in Stock - MarketBeat
Guardant Health (NASDAQ:GH) CTO Sells $567,122.04 in Stock - MarketBeat
Officer Freeman Acquires 808 Of Guardant Health Inc [GH] - TradingView — Track All Markets
Guardant Health Executives Sell Shares Worth Millions - TradingView — Track All Markets
Officer Chudova Sells 5,451 ($567.1K) Of Guardant Health Inc [GH] - TradingView — Track All Markets
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Guardant Health Inc Stock (GH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Monroe Terilyn J. | Chief People Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
17,555 |
0 |
38,545 |
| Kalia Kumud | Chief Information Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
21,237 |
0 |
43,916 |
| Freeman Chris | Chief Commercial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
27,237 |
0 |
54,032 |
| EAGLE CRAIG | Chief Medical Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
25,442 |
0 |
70,449 |
| Chudova Darya | Chief Technology Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
22,732 |
0 |
29,744 |
| Bell Michael Brian | Chief Financial Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
23,038 |
0 |
52,703 |
| Talasaz AmirAli | Co-Chief Executive Officer |
Dec 31 '25 |
Option Exercise |
0.00 |
4,815 |
0 |
2,002,689 |
| Talasaz AmirAli | Co-Chief Executive Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
23,997 |
0 |
2,024,245 |
| Eltoukhy Helmy | Co-Chief Executive Officer |
Dec 31 '25 |
Option Exercise |
0.00 |
4,815 |
0 |
2,051,958 |
| Eltoukhy Helmy | Co-Chief Executive Officer |
Jan 01 '26 |
Option Exercise |
0.00 |
23,997 |
0 |
2,073,514 |
2.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):